Nothing Special   »   [go: up one dir, main page]

BR112018003227A2 - uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma - Google Patents

uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma

Info

Publication number
BR112018003227A2
BR112018003227A2 BR112018003227A BR112018003227A BR112018003227A2 BR 112018003227 A2 BR112018003227 A2 BR 112018003227A2 BR 112018003227 A BR112018003227 A BR 112018003227A BR 112018003227 A BR112018003227 A BR 112018003227A BR 112018003227 A2 BR112018003227 A2 BR 112018003227A2
Authority
BR
Brazil
Prior art keywords
red blood
blood cell
disease
chlorite
way
Prior art date
Application number
BR112018003227A
Other languages
English (en)
Inventor
Kuehne Friedrich-Wilhelm
Maraprygsavan Paiboon
Original Assignee
Oxo Chemie Thailand Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxo Chemie Thailand Co Ltd filed Critical Oxo Chemie Thailand Co Ltd
Publication of BR112018003227A2 publication Critical patent/BR112018003227A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

método de tratamento de hiperglicemia induzida por doença/disfunção dos glóbulos vermelhos (rbcd) causada pela geração de produtos finais de glicação inicial e tardia. método de tratamento da anemia hemolítica, anemia hemolítica indolente, anemia falciforme, doenças hemorrágicas, derrame cerebral hemorrágico, sangramento hemorrágico. método de tratamento de rbcd para prevenir a progressão para complicações vasculares associadas à diabetes, denominadas como síndrome x, particularmente para prevenir a progressão para doença renal crônica, doença vascular coronariana e doença vascular periférica.
BR112018003227A 2015-08-20 2016-08-22 uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma BR112018003227A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562207774P 2015-08-20 2015-08-20
PCT/IB2016/055011 WO2017029648A1 (en) 2015-08-20 2016-08-22 Use of chlorite to treat red blood cell diseases and indications mediated thereby

Publications (1)

Publication Number Publication Date
BR112018003227A2 true BR112018003227A2 (pt) 2018-09-25

Family

ID=56896735

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018003227A BR112018003227A2 (pt) 2015-08-20 2016-08-22 uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma

Country Status (8)

Country Link
US (1) US11813234B2 (pt)
EP (1) EP3337489B1 (pt)
JP (2) JP6900596B2 (pt)
CN (1) CN108135930A (pt)
BR (1) BR112018003227A2 (pt)
CA (1) CA2995659A1 (pt)
RU (1) RU2018109574A (pt)
WO (1) WO2017029648A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168841A (zh) * 2019-07-05 2021-01-05 卢序 一种增加人一氧化氮生物利用度的方法
CN112386606A (zh) * 2019-08-19 2021-02-23 卢序 一种有第二信使作用增加积极氧化压力的氧化剂的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4369615B2 (ja) * 1997-10-06 2009-11-25 ディメサイド アーゲー 抗原特異的免疫応答を抑制するための化学的に安定化された亜塩素酸塩溶液の使用
CA2393136A1 (en) 1999-11-30 2001-06-07 Oxo Chemie Ag Evaluating and predicting clinical outcomes by gene expression analysis
EP1558237A4 (en) * 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID
WO2008047703A1 (en) * 2006-10-16 2008-04-24 Sekisui Chemical Co., Ltd. Hemoglobin determination method
EP2164502A1 (en) * 2007-06-01 2010-03-24 Dimethaid AG Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis
US20140287064A1 (en) * 2009-04-28 2014-09-25 Karen G. Swenholt Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument
CA2770023A1 (en) * 2009-08-06 2011-02-10 Neuraltus Pharmaceuticals, Inc. Treatment of macrophage-related disorders
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
WO2013093891A1 (en) * 2011-12-22 2013-06-27 Nuvo Research Gmbh Liposomal chlorite or chlorate compositions
EP2804612A4 (en) * 2012-01-19 2015-09-02 Ibt Pharma Inc THERAPEUTIC USES OF TETRACHLORODECAOXYGEN (TCDO)
US8748744B2 (en) * 2012-06-28 2014-06-10 Hubbell Incorporated Electrical box extender assembly
CN106413721A (zh) * 2014-05-16 2017-02-15 纽拉尔图斯制药公司 用于治疗巨噬细胞相关病症的方法和组合物

Also Published As

Publication number Publication date
RU2018109574A (ru) 2019-09-23
JP6900596B2 (ja) 2021-07-07
WO2017029648A1 (en) 2017-02-23
CA2995659A1 (en) 2017-02-23
JP2018523711A (ja) 2018-08-23
EP3337489B1 (en) 2023-01-18
JP2021130664A (ja) 2021-09-09
US20180243334A1 (en) 2018-08-30
CN108135930A (zh) 2018-06-08
US11813234B2 (en) 2023-11-14
EP3337489A1 (en) 2018-06-27
RU2018109574A3 (pt) 2020-02-27

Similar Documents

Publication Publication Date Title
WO2017062862A3 (en) Oligonucleotide compositions and methods thereof
BR112018016001A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MX2017010734A (es) Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
BR112019008384A2 (pt) composição farmacêutica, processos para tratamento e seus usos
BR112018011272A2 (pt) regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
GT201600084A (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso
MX2019002510A (es) Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado.
EA033286B1 (ru) Способ лечения или отсрочки развития хронической болезни почек
BR112016010454A2 (pt) métodos para tratar uma taupatia
EA201791898A1 (ru) Новые антитела, связывающиеся с tfpi, и содержащая их композиция
BR112017018963A2 (pt) método para tratar anemia por deficiência de ferro
AU2017261919A1 (en) Fat and medical uses thereof
BR112018003227A2 (pt) uso de clorito para tratar doenças dos glóbulos vermelhos e indicações mediadas desta forma
RU2011104958A (ru) Средство для комплексной терапии заболеваний, включающее дигидрокверцетин
WO2015051135A3 (en) Organic compositions to treat hepcidin-related diseases
WO2015027121A3 (en) Cancer treatment
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2018013203A (es) Ciclodextrinas como procoagulantes.
BR112016028402A2 (pt) toxina botulínica para uso no tratamento da paratonia
RU2016141712A (ru) Способ лечения инфильтратов после склеротерапии варикозного расширения вен
MX2018003954A (es) Metodos para mejorar la actividad de retinoides.
BR112015023404A2 (pt) sequestrantes de precursores de produto final de glicação avançada (age)
CY1124597T1 (el) Εκχυλισμα λαδιου gynura procumbens για τη θεραπεια διαφορων δερματολογικων ασθενειων και η διαδικασια παρασκευης του

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]